AVELLUM advises Horizon Capital on investment in Viseven

AVELLUM advised Horizon Capital on the acquisition of the minority stake in Viseven, a leading global marketing tech provider servicing the pharmaceutical and life sciences industry.

Founded in 2009, Viseven has expanded to over 30 countries, with development hubs in Ukraine, as well as Argentina, Estonia, India, Poland, and North America. Known as an innovator, the company has been constantly launching new products, including a digital content factory, cloud-based CRM and CLM suites powered by no-code functionality and enabled by AI tools, for an end-to-end digital marketing platform. Led by Nataliya Andreychuk (CEO), and co-founders Vyacheslav Vasylenko (COO) and Roman Vasylenko (CTO), Viseven services over 50 pharma and life sciences customers, and many of top-20 global companies, including Abbott, AbbVie, Amgen, Bayer, Biogen, Ipsen, Lilly, Novo Nordisk, Servier Laboratories, and others.

Horizon Capital is the leading private equity firm in Emerging Europe with over USD1.5 billion in AUM from investors with a capital base exceeding USD630 billion, raising circa USD0.8 billion in growth capital in just over five years, including USD328 million HCGF IV. The firm’s investment strategy focuses on backing visionary entrepreneurs leading fast-growing, primarily tech and export-oriented businesses in Ukraine and Moldova.

Mykola Stetsenko, the Managing Partner of AVELLUM, said: “It is an important step for Horizon Capital to continue investing in Ukraine. It shows fundamental faith of global investors in Ukraine and its prospects. Viseven is a leader in its field led by truly visionary entrepreneurs who continue creating new jobs in Ukraine. We are honoured to support Horizon Capital and are confident that this investment will take Viseven to the next level.”

AVELLUM assisted with the preparation and negotiation of the transaction documents and coordinated signing and completion of the transaction.

AVELLUM team was led by Managing Partner Mykola Stetsenko with support from senior associate Maryna Buinytska and associate Andrii Andryishyn. Mykyta Nota, Partner and Head of Competition Practice, led the competition law aspects of this transaction.

For more information on Horizon Capital’s investment in Viseven, please refer to the company’s press release available at the following link.